14-day Premium Trial Subscription Try For FreeTry Free
RSI low/high Values: [ 25 - 75 ]
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
AI Analysis of HROW
Powered by GPT-4
Upgraded!
Stock Analysis
Risk Assessment
Trading Strategy

Imprimis Pharmaceuticals stock price ended at $10.27 on Wednesday, after losing 0.484%.
(Updated on Apr 24, 2024)

Sell candidate since Apr 18, 2024 Loss -5.35% PDF

The Imprimis Pharmaceuticals stock price fell by -0.484% on the last day (Wednesday, 24th Apr 2024) from $10.32 to $10.27. During the last trading day the stock fluctuated 3.98% from a day low at $10.04 to a day high of $10.44. The price has fallen in 8 of the last 10 days and is down by -20.57% for this period. Volume fell on the last day along with the stock, which is actually a good sign as volume should follow the stock. On the last day, the trading volume fell by -266 thousand shares and in total, 389 thousand shares were bought and sold for approximately $4.00 million.

Given the current short-term trend, the stock is expected to rise 19.77% during the next 3 months and, with a 90% probability hold a price between $12.30 and $16.76 at the end of this 3-month period.

Ready to grow your portfolio? Here's your beginner's guide to opening a free brokerage account.

HROW Signals & Forecast

There are few to no technical positive signals at the moment. The Imprimis Pharmaceuticals stock holds sell signals from both short and long-term Moving Averages giving a more negative forecast for the stock. Also, there is a general sell signal from the relation between the two signals where the long-term average is above the short-term average. On corrections up, there will be some resistance from the lines at $10.94 and $11.69. A break-up above any of these levels will issue buy signals. A sell signal was issued from a pivot top point on Friday, April 05, 2024, and so far it has fallen -23.98%. Further fall is indicated until a new bottom pivot has been found. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell together with the price during the last trading day and this reduces the overall risk as volume should follow the price movements.

Support, Risk & Stop-loss for Imprimis Pharmaceuticals stock

Imprimis Pharmaceuticals finds support from accumulated volume at $10.25 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move much during the day (volatility) and with a large prediction interval from the Bollinger Band this stock is considered to be "high risk". During the last day, the stock moved $0.400 between high and low, or 3.98%. For the last week, the stock has had daily average volatility of 6.25%.

Imprimis Pharmaceuticals is oversold on RSI14 (17). Some stocks may drop long and hard while being oversold on RSI before turning, which increases the general risk.

Our recommended stop-loss: We hold a negative evaluation for this stock. No stop-loss is set.

Trading Expectations (HROW) For The Upcoming Trading Day Of Thursday 25th

For the upcoming trading day on Thursday, 25th we expect Imprimis Pharmaceuticals to open at $10.25, and during the day (based on 14 day Average True Range), to move between $9.59 and $10.95, which gives a possible trading interval of +/-$0.677 (+/-6.59%) up or down from last closing price. If Imprimis Pharmaceuticals takes out the full calculated possible swing range there will be an estimated 13.18% move between the lowest and the highest trading price during the day.

Since the stock is closer to the support from accumulated volume at $10.25 (0.19%) than the resistance at $10.52 (2.43%), our systems sees the trading risk/reward intra-day as attractive and believe profit can be made before the stock reaches first resistance..

Is Imprimis Pharmaceuticals stock A Buy?

The Imprimis Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe Imprimis Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

Current score: -1.715 Sell Candidate Unchanged

Predicted Opening Price for Imprimis Pharmaceuticals of Thursday, April 25, 2024

Fair opening price April 25, 2024 Current price
$10.25 ( 0.195%) $10.27

The predicted opening price is based on yesterday's movements between high, low, and closing price.

Trading levels for HROW

Fibonacci Support & Resistance Levels

Level Price
Resistance R3 10.65 3.70 %
R2 10.50 2.21 %
R1 10.40 1.29 %
Current price: 10.27
Support S1 10.10 -1.68 %
S2 10.00 -2.60 %
S3 9.85 -4.09 %

Accumulated Volume Support & Resistance Levels

Level Price
Resistance R3 11.50 11.98 %
R2 10.58 3.02 %
R1 10.52 2.43 %
Current price 10.27
Support S1 10.25 -0.195%
S2 9.95 -3.12%
S3 9.53 -7.21%

FAQ

What is the symbol for Imprimis Pharmaceuticals Stock and on which exchange is it traded?
The symbol for Imprimis Pharmaceuticals is HROW and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Imprimis Pharmaceuticals Stock?
The Imprimis Pharmaceuticals stock holds several negative signals and despite the positive trend, we believe Imprimis Pharmaceuticals will perform weakly in the next couple of days or weeks. Therefore, we hold a negative evaluation of this stock.

How to buy Imprimis Pharmaceuticals Stock?
Imprimis Pharmaceuticals Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Imprimis Pharmaceuticals Stock.

What's the current price of Imprimis Pharmaceuticals Stock?
As of the end of day on the Apr 24, 2024, the price of an Imprimis Pharmaceuticals (HROW) share was $10.27.

What is the 52-week high and low for Imprimis Pharmaceuticals Stock?
The 52-week high for Imprimis Pharmaceuticals Stock is $28.25 and the 52-week low is $7.60.

What is the market capitalization of Imprimis Pharmaceuticals Stock?
As of the Apr 24, 2024, the market capitalization of Imprimis Pharmaceuticals is 363.174M.

When is the next earnings date for Imprimis Pharmaceuticals?
The upcoming earnings date for Imprimis Pharmaceuticals is May 09, 2024.
Click to get the best stock tips daily for free!

About Imprimis Pharmaceuticals

Imprimis Pharmaceuticals Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharma... HROW Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT